News
Public · Published
JP Morgan maintains BioMarin Pharmaceutical at Overweight, lowers price target to $86 from $87
JP Morgan kept its Overweight rating on BioMarin Pharmaceutical but lowered its price target, its estimate of a possible share value, to $86 from $87. The article says the new target is 1.1% lower and implies 54.5% upside from the November 3 closing price of $55.66.
Published:
Updated:
What happened
JP Morgan kept its Overweight rating on BioMarin Pharmaceutical but lowered its price target, its estimate of a possible share value, to $86 from $87. The article says the new target is 1.1% lower and implies 54.5% upside from the November 3 closing price of $55.66.
Confirmed
Global impact / market context
The lower target slightly reduces JP Morgan’s stated estimate, while its Overweight rating remains unchanged. Investors may compare both signals with BioMarin’s recent analyst targets, because differing estimates can shape expectations about potential share value, but the article gives no company earnings or business update.
Analyst inference
The five most recent analyst notes in the article set targets from $60 to $119, a wide spread around JP Morgan’s $86 estimate. This shows analysts disagree on possible share value; the article does not establish why their views differ or predict trading effects.
Confirmed
What to watch
- Check whether JP Morgan makes further changes to its rating or $86 target; another adjustment would show whether this estimate is continuing to shift. Analyst inference
- Compare future analyst targets with the reported $60–$119 range, while treating those estimates as opinions rather than promised share prices. Analyst inference
- Look for company results or business updates that could provide evidence for or against analysts’ estimates; none are described in this article. Analyst inference
Evidence
- Original source link unavailable